Assessing Genmab (CPSE:GMAB) Valuation As Share Price Momentum Shows Signs Of Cooling [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
See our latest analysis for Genmab. Set against a 1 year total shareholder return of 27.9%, a 3 year total shareholder return of 33.4%, and a 5 year total shareholder return of 21.1%, Genmab's recent 7 day share price return of 3.5% and 90 day share price return of 4.1% suggest momentum has cooled lately as the market reassesses growth potential and risks around its oncology focused pipeline. If Genmab's recent moves have you reassessing your biotech exposure, this could be a good moment to look across other healthcare stocks that might fit your portfolio. With Genmab trading at DKK 2,007 and an intrinsic value estimate that implies a 72% discount, plus only a modest gap to the average analyst target, you have to ask: is this a genuine opportunity, or is future growth already priced in? With Genmab last closing at DKK 2,007 and the most followed narrative pointing to fair value around DKK 2,055, the gap is narrow but meaningful for anyone weighing the stock today. Strong re
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Business Wire
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)GlobeNewswire
- Is Genmab (CPSE:GMAB) Pricing Reflect Its Recent Biotech Momentum And DCF Upside Potential [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (GMAB): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance